Protein quality control in Alzheimers disease: The contentious role of ubiquilin-1

Future Neurology

Volumn 7, Issue 1, 2012, Pages 5-8

  Boehning, Darren ^a   Barral, José M ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

aging; Alzheimers disease; amyloid plaque; amyloid precursor protein; molecular chaperone; neurodegeneration; protein folding; proteostasis; ubiquilin 1

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CHAPERONE; UBIQUILIN 1; UBIQUITIN; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; DISEASE COURSE; HUMAN; NEUROPATHOLOGY; ONSET AGE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN QUALITY CONTROL; PROTEIN SYNTHESIS; REVIEW;

EID: 83655165314     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.11.62     Document Type: Review

References (20)

1. Thies W, Bleiler L; Alzheimers association. Alzheimers disease facts and figures. Alzheimers Dement. 7(2), 208-244 (2011).
2. Golde TE, Dickson D, Hutton M. Filling the gaps in the a beta cascade hypothesis of Alzheimers disease. Curr. Alzheimer Res. 3(5), 421-430 (2006). (Pubitemid 46066421)
3. Bertram L, Hiltunen M, Parkinson M et al. Family-based association between Alzheimers disease and variants in UBQLN1. N. Engl. J. Med. 352(9), 884-894 (2005). (Pubitemid 40300297)
4. Buchberger A. From UBA to UBX: new words in the ubiquitin vocabulary. Trends Cell Biol. 12(5), 216-221 (2002). (Pubitemid 34327613)
5. Walters KJ, Kleijnen MF, Goh AM, Wagner G, Howley PM. Structural studies of the interaction between ubiquitin family proteins and proteasome subunit S5a. Biochemistry 41(6), 1767-1777 (2002). (Pubitemid 34132251)
6. Hiyama H, Yokoi M, Masutani C et al. Interaction of hHR23 with S5a. The ubiquitin-like domain of hHR23 mediates interaction with S5a subunit of 26 S proteasome. J. Biol. Chem. 274(39), 28019-28025 (1999).
7. Su V, Lau AF. Ubiquitin-like and ubiquitin-associated domain proteins: significance in proteasomal degradation. Cell Mol. Life Sci. 66(17), 2819-2833 (2009).
8. Wu S, Mikhailov A, Kallo-Hosein H, Hara K, Yonezawa K, Avruch J. Characterization of ubiquilin 1, an mTOR-interacting protein. Biochim. Biophys. Acta 1542(1-3), 41-56 (2002).
9. Zhao G, Zhou X, Wang L et al. Structure of the mouse peptide N-glycanase-HR23 complex suggests co-evolution of the endoplasmic reticulum-associated degradation and DNA repair pathways. J. Biol. Chem. 281(19), 13751-13761 (2006). (Pubitemid 43855291)
10. Stieren ES, El Ayadi A, Xiao Y et al. Ubiquilin-1 is a molecular chaperone for the amyloid precursor protein. J. Biol. Chem. 286(41), 35689-35698 (2011).
11. N'Diaye EN, Kajihara KK, Hsieh I, Morisaki H, Debnath J, Brown EJ. PLIC proteins or ubiquilins regulate autophagy-dependent cell survival during nutrient starvation. EMBO Rep. 10(2), 173-179 (2009).
12. Wang H, Lim PJ, Yin C, Rieckher M, Vogel BE, Monteiro MJ. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin. Hum. Mol. Genet. 15(6), 1025-1041 (2006). (Pubitemid 43338242)
13. Petersen RC. Clinical practice. Mild cognitive impairment. N. Engl. J. Med. 364(23), 2227-2234 (2011).
14. Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurol. 9(8), 793-806 (2010).
15. Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature 475(7356), 324-332 (2011).
16. Kenyon CJ. The genetics of ageing. Nature 464(7288), 504-512 (2010).
17. Smemo S, Nowotny P, Hinrichs AL et al. Ubiquilin 1 polymorphisms are notassociated with late-onset Alzheimers disease. Ann. Neurol. 59(1), 21-26 (2006). (Pubitemid 43042867)
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 34(7), 939-944 (1984). (Pubitemid 14076461)
19. Selkoe DJ. Resolving controversies on the path to Alzheimers therapeutics. Nat. Med. 17(9), 1060-1065 (2011).
20. Karran E, Mercken M, Strooper BD. The amyloid cascade hypothesis for Alzheimers disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10(9), 698-712 (2011).